RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 — Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. (“VelosBio” or the...
TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.